Sermorelin Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Sermorelin evidence and protocol review

Growth Signal Research peptide Lyophilized verified

Also known as: GRF 1-29, GHRH 1-29

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

2 mg, 5 mg, 10 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Catalog Description

Sermorelin is a 29-amino-acid fragment matching the biologically active N-terminal sequence of endogenous human GHRH. It was FDA-approved as Geref for diagnostic and pediatric GH-deficiency use, but the manufacturer withdrew it from the US market in 2008 for commercial (not safety) reasons. It is still prescribed via compounding pharmacies and remains a reference GHRH agonist in GH-axis research, generally shorter-acting than DAC-modified analogs.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Short-acting GHRH analog; use study-specific pharmacokinetics and do not borrow the multi-day CJC-1295-DAC half-life

Onset

Rapid GH pulse per dose

Administration Routes (Research)

IV for historical diagnostic testingSC in historical pediatric treatment studies

Reported Research Effects

Stimulates endogenous GH release via GHRH receptor agonism
Historic pediatric GH-deficiency diagnostic/treatment use

Reported Research Side Effects

Transient facial flushing
Injection-site pain
GH and IGF-I elevation require indication-specific monitoring
Long-term adult-height effect was not established
Modern anti-aging and adult-wellness protocols were not part of the historical approval

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

1 mcg/kg as a single IV dose used with conventional provocative testing for growth-hormone deficiency [IV; Historical diagnostic use; Single clinician-administered test]Source: PMID 18031173
30 mcg/kg SC once daily at bedtime for 12 months in limited prepubertal idiopathic growth-hormone-deficiency data [SC; Historical pediatric treatment study; Nightly]Source: PMID 18031173
30 mcg/kg/day by continuous SC infusion or in three divided SC doses was studied but produced less height-velocity increase than once-daily somatropin in the review [SC; Historical comparator regimens; Continuous or three divided daily doses]Source: PMID 18031173

Research Notes

GEREF was discontinued for reasons other than safety or effectiveness. The record now preserves both the historical diagnostic and pediatric treatment protocols and clearly excludes unsupported adult anti-aging schedules.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Sermorelin diagnosis and pediatric-treatment review — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/18031173/

GEREF sermorelin FDA approval package — U.S. Food and Drug Administration
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019863_S001_GEREF.pdf

FDA determination on discontinued GEREF presentations — Federal Register
https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.